NAD+ Injections: The Longevity Claims vs the Evidence

NAD+ injections deliver an essential coenzyme directly into the body, on the theory that topping up declining NAD+ levels can restore energy and slow aging. NAD+ itself is real and important biology, but the marketing has sprinted past the evidence: there are no placebo-controlled trials establishing the wellness benefits, and NAD+ injections are not FDA-approved for anti-aging, energy, or wellness. Any use should be provider-supervised.

This article explains what NAD+ is, what the human evidence does and does not show, how the delivery routes compare, and a realistic verdict. It is not a dosing guide or a recommendation to use it.

What NAD+ is

NAD+ (nicotinamide adenine dinucleotide) is a coenzyme found in every cell, and it is genuinely essential, not a fringe substance. It plays central roles in cellular energy metabolism (it shuttles electrons in the reactions that produce ATP), in DNA repair via PARP enzymes, and in activating sirtuins, a family of proteins (SIRT1 through SIRT7) linked to cellular stress responses and, in animal studies, to aspects of aging.

NAD+ levels decline with age and in some chronic conditions. That decline is the seed of the entire injectable-NAD+ industry: the logic is that if low NAD+ accompanies aging and fatigue, then restoring it should help. The biology behind that logic is real. Whether injecting NAD+ delivers the promised real-world results is a separate question, and a much less settled one.

This is the recurring pattern across the wellness-peptide and wellness-infusion space, and it is worth naming directly. A compound with a genuine, important biological role gets extrapolated into a sweeping benefit claim that the human evidence has not earned. It is the same gap that runs through the nootropic peptides and the longevity peptides: interesting biology, thin outcome data, confident marketing. NAD+ is a textbook example, because almost no one disputes that the coenzyme matters, only whether topping it up by injection does what the clinics imply.

How it is delivered

NAD+ is offered in a few forms, and they get marketed somewhat interchangeably even though they differ.

• IV infusion delivers NAD+ directly into the bloodstream, bypassing absorption. It is the original clinical route and is typically slow, because rapid infusion causes discomfort (chest tightness, nausea).
• Subcutaneous injection is promoted as a cheaper, more convenient, at-home-friendly alternative to sitting through a drip. The tradeoff is that absorption from a subcutaneous depot is less characterized.
• Oral precursors, NMN (nicotinamide mononucleotide) and NR (nicotinamide riboside), are not NAD+ itself but molecules the body converts into NAD+ in tissues. They are the most accessible and have their own developing evidence base.

The table below frames the practical differences. It is not an endorsement of any route, and the benefit column reflects how thin the human outcome data is across the board.

Route	How it is given	Evidence and benefit	Practical notes
IV infusion	Slow drip in a clinic	Some observational use in addiction medicine; no RCTs for wellness	Costly (often $200-$800+ per session); time-intensive; discomfort if fast
Subcutaneous injection	Small injection, often at home	Thin absorption and benefit data	Cheaper and more convenient; quality of compounded product varies
Oral precursors (NMN/NR)	Capsule or powder	Developing evidence base; converted to NAD+ in tissues	Most accessible; does not require injection

What the evidence actually shows

Here is the honest state of the science, separated by claim.

Addiction medicine is the one area with a real history: NAD+ IV has been used since the 1960s for opioid and alcohol withdrawal, and some clinical observational data exists for that application. That is the original, non-cosmetic use case.

Anti-aging, energy, and wellness, the claims that drive the clinic industry, are not established. There are no placebo-controlled randomized trials demonstrating benefit on these endpoints. A 2024 randomized pilot (a medRxiv preprint, not yet peer-reviewed) found that subjective improvement was common but that there was no confirmed placebo-controlled benefit on objective energy or fatigue measures, which is exactly the pattern you would expect if much of the perceived effect were placebo or expectation. A 2026 systematic review in Frontiers in Aging found short-term tolerability favorable, with no consistent serious safety signals, but described the benefit on wellness-relevant endpoints as "limited and heterogeneous."

The summary that fits the data: the underlying biology is promising, and short-term safety looks reasonable, but the wellness benefit is preliminary at best and not confirmed in controlled trials. Confidence in the marketed claims is low.

A specific point deserves emphasis, because it is where the marketing is most misleading. Much of the popular case for NAD+ injections is built on animal and cell studies, where raising NAD+ or activating sirtuins produces striking effects, and on the general observation that NAD+ falls with age. Neither of those establishes that injecting NAD+ into a person reverses aging or reliably restores energy. The history of aging research is full of interventions that looked spectacular in mice and did little in humans, and NAD+ has not yet cleared that bar. The honest reader should hold the mouse data and the human data separately, and weight decisions on the human data, which is sparse.

Regulatory status

NAD+ injections and infusions are not FDA-approved as a drug for anti-aging, energy, or wellness. They are administered as compounded products on an off-label basis, with no standardized, FDA-reviewed protocol behind them. They are widely available at IV wellness clinics, a fast-growing category, but regulatory oversight of that category is thin. Availability is not approval, and a clinic offering something is not evidence that it works.

For competitive athletes, NAD+ is not on the WADA Prohibited List, so it is not a doping concern in itself, though athletes should always verify the current list.

Safety considerations

The safety picture from short-term studies is reassuring on serious events but not on comfort or the gaps in long-term data. Reported effects include nausea, flushing, and, with IV administration, phlebitis (vein irritation) and infusion-site issues. IV access also carries an inherent infection risk, and any injectable carries sterility concerns when the product is compounded outside tightly regulated channels. No documented serious safety signals appeared in the short-term studies, but "no signal in small short-term studies" is not the same as "established long-term safety."

Cost is also a practical safety-adjacent factor: IV sessions commonly run several hundred dollars each, and an unproven benefit at that price is worth weighing honestly. Oral precursors (NMN, NR) are far more accessible and carry their own, arguably better-characterized, evidence base, which is worth raising with a provider before committing to injections.

What to ask a provider

If NAD+ comes up, a licensed clinician is the right person to pressure-test it with. Useful questions:

• Given that benefit is not established in controlled trials, what would I realistically expect?
• Does the IV or injectable route offer anything over oral precursors for my goal?
• How are infection and product-quality risks managed?
• Is the cost justified by the evidence, or is this largely a wellness purchase?

Where Myo fits

NAD+ protocols rarely run alone; they often sit alongside other injectables and supplements in a broader self-care routine, which is exactly where scheduling and dosing can collide. Myo keeps the full injection schedule in one organized log, so doses, sites, and timing stay separated and visible, and the app's check-ins let you track the subjective energy and wellness claims that NAD+ is sold on, turning "I think I feel better" into a trend you can actually inspect against placebo expectations.

For anyone using NAD+ in pursuit of body or performance goals, the harder truth is that the proven levers lie elsewhere. Our body composition tracking guide covers how to measure what is actually changing, so an unproven adjunct does not get credit the data does not support.

The bottom line: NAD+ is real, essential biology, but injecting it for energy or longevity is a case of marketing well ahead of evidence. It is not FDA-approved for those uses, the wellness benefit is unconfirmed in controlled trials, and oral precursors may be the more sensible starting point. Keep expectations grounded and any use provider-led.

References

• Frontiers in Aging. NAD+ IV therapy: systematic review (2026). https://www.frontiersin.org/journals/aging/articles/10.3389/fragi.2026.1652582/full
• medRxiv. Randomized pilot of NAD+ therapy (2024 preprint). https://www.medrxiv.org/content/10.1101/2024.06.06.24308565v1.full
• ScienceDirect. PRISMA review of NAD+ interventions (2026). https://www.sciencedirect.com/article/pii/S1568163726000498